WINSFORD: Advanced Medical Solutions Group has acquired French company Biomatlante SA, a well-established international developer and manufacturer of innovative surgical biomaterial technologies for €8 million, with a potential further up to €0.3 million due over the next two years.

Advanced is the surgical and advanced wound care specialist company. The acquisition will strengthen AMS’s product portfolio, R&D pipeline, and market access.

It provides the Group with a range of revenue-generating surgical products and an R&D pipeline of complementary biosurgical technologies and offers significant growth potential in additional surgical markets estimated to be worth $0.5 billion. The Acquisition is expected to be marginally earnings enhancing in the first full year of ownership.

Biomatlante’s biosurgical products, which are sold mainly in Europe, are complementary to AMS’s surgical product portfolio and generated sales of more than €4 million in 2018. AMS anticipates increasing the sales of these products in other jurisdictions through its existing global commercial infrastructure, as well as leveraging Biomatlante’s established presence in France for the Group’s existing surgical product portfolio.

The R&D pipeline and platform technologies which AMS acquired will broaden the Group’s biosurgical technology offering while also offering multiple synergies across the sales, marketing, regulatory, operational divisions and R&D.

For its financial year ended 31 December 2018, Biomatlante reported revenue of more than €4 million and a net profit of approximately €0.2 million. As at 31 December 2018, Biomatlante reported gross assets of approximately €2.4 million.

Commenting on the acquisition, Chris Meredith, CEO of AMS, said: “This acquisition is in line with our strategy to acquire technologies that are complementary to our surgical portfolio and allow us to leverage our global routes to market. The acquisition grants AMS access to multiple new markets, including the synthetic bone substitutes market which is estimated at $0.5 billion. We are excited to welcome the Biomatlante team to AMS and look forward to working together with them to accelerate the commercial success internationally and to continue to develop the Biomatlante technology in a wide range of potential applications and indications.”

Commenting this acquisition, Chantal GOBIN-DACULSI, Co-founder and President of Biomatlante said: “This is an important stragecic step for Biomatlante and we are excited to become part of the AMS group. AMS is a high quality global Company with the scale, expertise and track record of realising the value of scienitific innovation and rapidly growing the sales of marketed products. Our product portfolios, product pipelines and geographic footprints are highly complementary, and, as part of the AMS family, the know-how of our team can be fully realised, allowing our pipeline of synthetic bone substitutes to be commercialised on a global scale.”